Trial Design of Abstract 150O_PR (IMAGE)

European Society for Medical Oncology

Trial Design of Abstract 150O_PR

Caption

Trial design of abstract 150O_PR "Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC)- The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)" by J. Huober et al

Credit

European Society for Medical Oncology

Usage Restrictions

Image to be used only in connection with this release

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.